India’s drug price regulator has mandated strict adherence to revised maximum retail prices for 137 non-scheduled anti-cancer drugs following trade margin cuts. State Drug Controllers have been instructed to monitor compliance, with overcharging proceedings threatened for violators.

India’s drug price regulator, the National Pharmaceutical Pricing Authority (NPPA), has issued an office memorandum instructing manufacturers, retailers, dealers, stockists, hospitals, and medical institutions to strictly follow revised maximum retail prices (MRPs) for 137 non-scheduled anti-cancer drugs.

According to the memorandum issued on November 11, the revised prices officially took effect on November 9. The regulatory action follows trade margin cuts aimed at lowering the cost of critical cancer treatments for patients.

Under the order, every retailer, dealer, hospital, and medical institution is required to prominently display the revised price lists at their physical premises as well as on their official websites. Furthermore, hospitals and medical institutions are specifically tasked with monitoring the MRPs of these formulations to ensure full compliance.

The NPPA has also directed State Drug Controllers (SDCs) to closely monitor compliance across manufacturers, dealers, and healthcare facilities. The authority warned that any violations will trigger overcharging proceedings under the provisions of the Drugs (Prices Control) Order (DPCO) of 2013.

To support enforcement, the regulator has provided mechanisms for patients and the public to report issues such as overcharging, drug shortages, or non-availability. Grievances can be submitted via the Pharma Sahi Daam app and portal, through a dedicated helpline at 1800-111-255, or via email to monitoring-nppa@gov.in.

"The strict enforcement of revised pricing for essential medicines like anti-cancer drugs highlights the critical balance between regulatory compliance and affordability in the healthcare sector. For businesses operating in life sciences, healthcare delivery, and pharmaceutical distribution, transparency in pricing and adherence to the Drugs Prices Control Order are paramount. Companies must proactively update their digital platforms and physical outlets to maintain compliance and avoid severe overcharging penalties." — Dr. Shishir Gupta, Founder & CEO, StartupLanes

Recent StartupLanes Articles

Browse through our 30 latest publications on venture capital, startups, and angel investing.

Adani Energy Solutions Completes ₹3,050-Crore Acquisition of IntelliSmart Nov 17, 2026
Shriram Properties Reports 151% Rise in Q2 Net Profit at ₹21.6 Crore Nov 17, 2026
Mumbai Property Registrations Reach Four-Year Diwali High with 13% Revenue Growth Nov 17, 2026
India and US Negotiate Interim Trade Agreement Focusing on Goods and Tariff Advantages Nov 17, 2026
INOX Air Products Plans 27% Capacity Expansion Following SEBI DRHP Filing Nov 17, 2026
Bay of Bengal Prepares for Potential Third Cyclone of North-East Monsoon Nov 17, 2026
Royal Enfield Unveils Himalayan 750 Featuring New Parallel-Twin Engine and Advanced Specifications Nov 17, 2026
Essar’s Technology Arm Black Box Reports 31% Rise in September Quarter Net Profit Nov 17, 2026
Mangaluru Central Station Redevelopment Estimated at ₹94 Crore, Hassan-Mangaluru Line Doubling Planned Nov 17, 2026
India’s Logistics Sector Faces Significant Manpower Shortage, Requires 43 Lakh Workers by 2030 Nov 17, 2026
Tata Sons Rejects Noel Tata's Request for Audio-Video Recording of September Board Meeting Nov 16, 2026
Rupee Declines 8 Paise to Close at 94.20 Against US Dollar Amid Stronger Greenback and Weak Equities Nov 16, 2026
Gillette India Reports 11% Rise in Q2 Net Profit at ₹159 Crore on Cost Savings Nov 16, 2026
TRAI Data Reveals Reliance Jio Recorded Fewer Actionable Spam Complaints Than Airtel and Vi in Q3 Nov 16, 2026
India’s Exports to US Rise 11% to $50.80 Billion in April-September FY27 Amid Trade Talks Nov 16, 2026